Open AccessJAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease
Author(s) -
Maulik Patel,
Sadakatsu Ikeda,
Susan R. Pilat,
Razelle Kurzrock
Publication year - 2017
Publication title -
jama dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.128
H-Index - 166
eISSN - 2168-6084
pISSN - 2168-6068
DOI - 10.1001/jamadermatol.2016.5554
Subject(s) - medicine , dermatology , disease , castleman disease , oncology
Castleman disease (CD) is an ultrarare, interleukin-6 (IL-6)-driven lymphoproliferative disorder whose underlying molecular alterations are unknown. Siltuximab (anti-IL-6 antibody) is approved for treatment of this disease. To our knowledge, genomic sequencing of CD has not been reported.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom